Basket | Login


Actinogen Medical completes recruitment of participants for its Phase II clinical trial of Xanamem for AD

Sunday 25 November 2018

On 25 November, the Australian biotechnology company Actinogen Medical focused on innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases, announced that it has recruited its final participant into Phase II XanADu clinical trial. The study is investigating Xanamem, which is a drug candidate designed to block the excess production of cortisol in the brain. The Phase II trial is a 12-week, double-blind, randomised, placebo-controlled study investigating the safety, tolerability and efficacy of Xanamem in people with mild dementia due to Alzheimer’s disease (AD).  XanADu started recruitment in 2017 and has enrolled 186 participants. Results are expected in Q2 2019.